Par Pharmaceutical v. Zydus Cadila: Varenicline Patent Dispute Dismissed Without Prejudice
Par Pharmaceutical and Endo Par Innovation sued Zydus Cadila in Delaware over two patents covering nitrosamine impurity control in varenicline (Chantix) tablets. After 500 days of litigation, both parties stipulated to dismiss all claims and counterclaims without prejudice — leaving the door open for future enforcement.
Chantix Nitrosamine Patents: A Delaware ANDA Dispute Left Unresolved
Filed on 8 August 2023 in the District of Delaware, this Hatch-Waxman-style infringement action pitted Par Pharmaceutical, Inc. and Endo Par Innovation Company, LLC against Zydus Cadila and its affiliate Zydus Lifesciences Ltd. The plaintiffs asserted two patents — US11717524B1 and US11779587B2 — directed at controlling nitrosamine impurities in varenicline tartrate formulations, the active ingredient in Pfizer’s smoking-cessation drug Chantix. Zydus sought to commercialise generic varenicline tablets in 0.5 mg and 1 mg dosage strengths.
On 20 December 2024, after approximately 500 days of litigation, the parties filed a stipulated dismissal under Federal Rules of Civil Procedure 41(a) and 41(c), agreeing to terminate all claims, counterclaims, and affirmative defences without prejudice and without any award of costs or attorneys’ fees to either party. The without-prejudice designation is legally significant: Par retains the right to assert these same patents against Zydus in a future proceeding, and Zydus’s invalidity and non-infringement counterclaims are likewise preserved.
A 500-day duration before a no-costs, without-prejudice dismissal suggests the parties may have reached a commercial accommodation — such as a confidential licence, consent judgement, or agreed market-entry date — though the public record is silent on terms. The timing also coincides with ongoing FDA and industry scrutiny of nitrosamine impurities across multiple drug classes, which may have influenced both parties’ calculus on litigation risk and commercial strategy. Whether Par pursues Zydus or other ANDA filers under these patents remains an open question.
Filing to Dismissed without Prejudice in 500 days
500 days from filing to dismissal — above the median ANDA pharma dismissal timeline
Dismissed without prejudice: what the stipulated exit means for both parties
Rules 41(a) and 41(c): a consensual, consequence-free exit
A stipulated dismissal under FRCP 41(a) and 41(c) requires agreement from all parties and extinguishes the current action without a merits ruling. Crucially, the without-prejudice designation means neither claim preclusion nor issue preclusion attaches — Par can re-file infringement claims on US11717524B1 and US11779587B2, and Zydus retains its invalidity defences. No finding on patent validity or infringement was made.
No merits adjudicationWithout prejudice: the distinction that keeps both options alive
A ‘without prejudice’ dismissal contrasts sharply with a ‘with prejudice’ exit, which would bar Par from ever re-asserting these patents against Zydus. Here, the public record confirms only that litigation ended by stipulation with no costs to either party — it is silent on whether a settlement, licence, or agreed launch date underlies the dismissal. Attorneys and product teams should not treat this as a cleared path for Zydus’s generic launch without independent FTO analysis.
Re-filing preservedPar retains full enforcement rights against Zydus and other filers
By exiting without prejudice, Par (and Endo Par Innovation) preserve the ability to reassert US11717524B1 and US11779587B2 at any time within the applicable statute of limitations. This is consistent with a licensor strategy: resolve one ANDA filer through a private arrangement while keeping the patents live for enforcement against other generic entrants. Par’s retention of Farnan LLP and a nine-attorney team suggests continued IP activity in this space.
Enforcement rights intactZydus exits without an invalidity ruling — a double-edged outcome
Zydus avoids a potentially adverse infringement judgment, but equally foregoes an invalidity or non-infringement ruling that could have cleared its path to market and created estoppel benefits for other generic competitors. The absence of a costs award removes any financial sting. Zydus’s commercial freedom to launch generic varenicline remains legally uncertain unless a private agreement governs its market-entry rights — the public record does not confirm this.
No cleared FTOFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Par Pharmaceutical, Inc. | Company | Pharmaceutical patent holder — asserting US11717524B1 and US11779587B2 for varenicline nitrosamine impurity controlSearch in Eureka ↗ |
| Co-Plaintiff | Epic Par Innovation Company, LLC | Company | Search in Eureka ↗ |
| Co-Plaintiff | Endo Par Innovation Company, LLC | Company | Search in Eureka ↗ |
| Defendant | Zydus Cadila | Individual | Generic pharmaceutical manufacturer seeking to market 0.5 mg and 1 mg varenicline tablets in the USSearch in Eureka ↗ |
| Co-Defendant | Zydus Lifesciences Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Brian M. Goldberg | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel R. Roberts | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan D.J. Loeb | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Martin J. Black | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert D. Rhoad | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sharon K. Gagliardi | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Shyam Shanker | Attorney | Counsel for Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Farnan LLP | Law Firm | Representing Par Pharmaceutical, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexis Stombaugh | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Carolyn A. Blessing | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Jacob C. Britz | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | James T. Peterka | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Jennifer Siew | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Michael J. Gaertner | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Mikaella Evaristo | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Pilar Gabrielle Kraman | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Terrence P. Canade | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant counsel | Zhibin Li | Attorney | Counsel for Zydus CadilaSearch in Eureka ↗ |
| Defendant law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing Zydus CadilaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal under FRCP 41(a) and 41(c) is notable for what it does not contain: no finding of validity, no infringement ruling, and no claim construction. The explicit ‘without prejudice’ language, combined with a mutual waiver of costs, reflects a balanced exit that preserves legal positions symmetrically. This phrasing is consistent with an underlying commercial arrangement — possibly a licence or agreed non-launch period — though the filed stipulation is silent on any such terms. Neither party can assert res judicata or collateral estoppel from this proceeding.
US11717524B1 & US11779587B2 — Nitrosamine Impurity Control in Varenicline
US11717524B1 (application no. US17/930824) and US11779587B2 (application no. US18/148659) protect methods and compositions directed at controlling nitrosamine impurities in varenicline tartrate — the API in Pfizer’s Chantix, a leading prescription smoking-cessation therapy. Nitrosamines are probable human carcinogens regulated under FDA guidance issued from 2018 onward; patents in this space address formulation techniques, manufacturing controls, and impurity thresholds that generic manufacturers must navigate to obtain FDA approval.
Strategically, these patents represent a second-wave enforcement layer beyond varenicline’s original composition-of-matter protection. They are designed to extend the commercial window for branded or authorised generic versions by requiring ANDA filers to certify non-infringement or invalidity under Paragraph IV — triggering litigation and a 30-month stay. For the pharmaceutical sector, this case illustrates how impurity-related patents can function as effective market-exclusivity tools even after primary composition patents have expired or are nearing expiry.
Should your R&D team run an FTO against US11717524B1 and US11779587B2?
Any company developing, manufacturing, or filing an ANDA for a varenicline generic product — or any drug requiring nitrosamine impurity management under current FDA guidance — should evaluate freedom-to-operate against US11717524B1 and US11779587B2 before filing. The without-prejudice dismissal in this case confirms Par has not abandoned enforcement; it retains full rights to assert these patents against future ANDA filers. The risk window is especially acute for 505(b)(2) applicants and authorised generic partners.
PatSnap Eureka’s FTO Search Agent can map the claims of US11717524B1 and US11779587B2 against your product’s manufacturing process, impurity control specification, and formulation approach — identifying claim elements that may require design-around or licensing. Eureka can also identify related nitrosamine patent families from Par, Endo, and third parties, giving your IP and regulatory teams a consolidated risk landscape before FDA submission.
Run a freedom-to-operate analysis on US11717524B1 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Nitrosamine & Varenicline Patent Cases in Delaware
Explore comparable Hatch-Waxman patent infringement cases involving varenicline, nitrosamine impurity patents, and ANDA generic challenges litigated in Delaware District Court.
What this case signals for the nitrosamine and generic drug IP landscape
Varenicline’s nitrosamine impurity patents are active enforcement tools — this dismissal signals strategic positioning, not patent weakness.
Nitrosamine patents are a live enforcement risk for ANDA filers across multiple drugs
FDA pressure on nitrosamine impurities has prompted a wave of new patents covering formulation and purification approaches. Par’s assertion of US11717524B1 and US11779587B2 demonstrates that impurity-control patents can anchor Hatch-Waxman litigation. Any generic manufacturer in the varenicline, metformin, or sartan space should assess nitrosamine-related patent exposure before ANDA submission.
Without-prejudice dismissals often mask private licence or consent arrangements
A 500-day dispute resolved with no costs and no merits ruling is consistent with a confidential settlement or agreed launch window. Industry practitioners should monitor Zydus’s FDA approval status and any subsequent market activity as a proxy for whether a private arrangement governs its entry. Similar structures have appeared in other late-stage ANDA cases resolved without trial.
Par v Zydus — key questions answered
Par Pharmaceutical and Endo Par Innovation asserted two patents: US11717524B1 (application US17/930824) and US11779587B2 (application US18/148659). Both patents cover nitrosamine impurity control in varenicline tartrate formulations — the active ingredient in Chantix — in connection with Zydus’s ANDA for generic varenicline tablets in 0.5 mg and 1 mg strengths.
Dismissed without prejudice means the court made no ruling on the merits — no finding of infringement, validity, or claim construction. Par retains the right to reassert US11717524B1 and US11779587B2 against Zydus in a future proceeding. Zydus likewise preserves its invalidity and non-infringement defences. Neither party is bound by this dismissal in any subsequent litigation.
The public record reflects only a stipulated dismissal under FRCP 41(a) and 41(c) — without prejudice and without costs to either party. The filing is silent on any settlement, licence, or agreed launch date. The 500-day duration and no-costs structure are consistent with a private commercial arrangement, but this cannot be confirmed from available court documents.
FDA guidance issued from 2018 onward requires generic manufacturers to assess and control nitrosamine impurities — probable carcinogens — in drug products. Patent holders have obtained patents covering specific impurity thresholds, formulation techniques, and manufacturing controls. ANDA filers must certify non-infringement or invalidity of such patents under Paragraph IV, triggering the 30-month stay mechanism and potential litigation, as occurred here.
The dismissal without prejudice does not grant Zydus cleared freedom to operate. It resolves the current litigation but leaves the underlying patents enforceable. Zydus’s commercial ability to launch depends on FDA approval status, any private agreement with Par (not disclosed in the public record), and whether Par elects to refile. Independent FTO analysis against US11717524B1 and US11779587B2 is advisable before any commercial launch decision.
PatSnap Eureka searches patents and litigation data to answer instantly.